Achillion Pharmaceuticals, Inc.
300 George Street
New Haven
Connecticut
06511
United States
Tel: 203-624-7000
Fax: 203-624-7003
Website: http://www.achillion.com/
245 articles with Achillion Pharmaceuticals, Inc.
-
BioSpace Movers and Shakers: Feb. 15
2/15/2019
Pharma and biotech companies strengthen their leadership teams with new hires and appointments at Cadent, bluebird, Abeona, Sanofi, and more. -
Achillion Appoints Brian Di Donato as Chief Financial Officer
2/11/2019
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced the appointment of Brian Di Donato to the position of Senior Vice President and Chief Financial Officer, effective immediately.
-
BioSpace Movers and Shakers: Jan. 4
1/4/2019
Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more. -
Movers and Shakers for Sept. 17
9/17/2018
Let's take a look at some of the professionals moving to transition the pharma and biotech world this past week. -
Achillion is handing out pink slips to 20 percent of its employees and initiating an operational restructuring plan.
-
Achillion Initiates Phase I First-in Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D
12/20/2017
This initial phase 1 trial is a randomized, placebo-controlled, single-ascending dose study of ACH-5228 administered to healthy volunteers.
-
Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy (C3G) and the Initiation of a Phase 1 Extended-Release Bioavailability Study
12/18/2017
This designation may provide, under specified conditions, for a seven-year marketing exclusivity period, as well as certain incentives, including federal grants, tax credits and a waiver of PDUFA filing fees.
-
Achillion Announces Pricing of Secondary Offering Of Common Stock
11/16/2017
The offering is expected to close on November 20, 2017, subject to the satisfaction of customary closing conditions.
-
Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G
11/15/2017
Greater than 50% improvement in proteinuria (albumin to creatinine ratio) after 14 days of oral dosing with ACH-4471.
-
Achillion Announces Proposed Secondary Offering of Common Stock
11/15/2017
Achillion will not sell any shares or receive any proceeds from the offering, and the total number of shares of its outstanding common stock will not change as a result of the offering.
-
The EMA Committee for Orphan Medicinal Products also issued a positive opinion on ACH-4471 for orphan status in the European Union for the treatment of PNH.
-
USPTO Grants Composition of Matter Patent to Achillion for ACH-4471, First-in-Class Small Molecule Complement Alternative Pathway Factor D Inhibitor
10/24/2017
This issued patent will be the eighth patent that the USPTO has granted to Achillion this year on its complement factor D portfolio.
-
Achillion Announces Presentation of Data From OMEGA-1 Phase IIb Trial With Odalasvir, AL-335, and Simeprevir (JNJ-4178) at the 2017 Liver Meeting
10/23/2017
98.9% SVR12 achieved following six weeks of therapy for patients with chronic HCV genotypes 1, 2, 4, 5, or 6.
-
Achillion Announces Strengthening Of Management Team
9/11/2017
-
Achillion Shares Surge on Promising ACH-4471 Phase II Data
8/9/2017
-
Achillion Reports Second Quarter 2017 Financial Results And Proof-Of-Concept With A First-In-Class, Oral Factor D Inhibitor
8/9/2017
-
Achillion To Host Second Quarter 2017 Results Conference Call On August 8, 2017
8/2/2017
-
Achillion Announces Key Promotion And Discovery Organization Change
7/11/2017
-
Achillion Reports First Quarter 2017 Financial Results And Provides Update On Clinical Programs
5/4/2017
-
Achillion Announces Additional Phase II Results Including 100% SVR24 For Genotype 1 HCV After 6-Weeks Of Once Daily JNJ-4178
4/24/2017